Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Diagnostics ; 11(4):09, 2021.
Article in English | MEDLINE | ID: covidwho-1209859


Accurate phenotyping of patients with pulmonary hypertension (PH) is an integral part of informing disease classification, treatment, and prognosis. The impact of lung disease on PH outcomes and response to treatment remains a challenging area with limited progress. Imaging with computed tomography (CT) plays an important role in patients with suspected PH when assessing for parenchymal lung disease, however, current assessments are limited by their semi-qualitative nature. Quantitative chest-CT (QCT) allows numerical quantification of lung parenchymal disease beyond subjective visual assessment. This has facilitated advances in radiological assessment and clinical correlation of a range of lung diseases including emphysema, interstitial lung disease, and coronavirus disease 2019 (COVID-19). Artificial Intelligence approaches have the potential to facilitate rapid quantitative assessments. Benefits of cross-sectional imaging include ease and speed of scan acquisition, repeatability and the potential for novel insights beyond visual assessment alone. Potential clinical benefits include improved phenotyping and prediction of treatment response and survival. Artificial intelligence approaches also have the potential to aid more focused study of pulmonary arterial hypertension (PAH) therapies by identifying more homogeneous subgroups of patients with lung disease. This state-of-the-art review summarizes recent QCT developments and potential applications in patients with PH with a focus on lung disease.

Indian Journal of Traditional Knowledge ; 19:69-80, 2020.
Article in English | Scopus | ID: covidwho-1130241


Ayurveda, a branch of AYUSH system of health care in India is considered as alternative/complementary of medicine (CAM) in WHO. Here, its products are covered under “drug and cosmetics” act but in abroad they are supplements or functional foods. The aim of Ayurveda is to maintain the wellness of a healthy person and to treat a patient. For treatment, Ayurveda adopts 3 approaches i.e., (1) Daivavyapasharya chikitsa) (ypareht enivid 2 ( Yuktivyapashraya chikitsa (Rational therapy) 3 Satvavajaya chikitsa (Psychotherapy) and focuses to enhance the Vyadhikshmatwa (capacity to fight against spread of pathogenesis by strengthening all 7 dhatus (rasa, rakta, meda, mansa, asthi, majja and shukra). The disease COVID-19 falls under “Bhootvidya (GrahaVidya)", which is one of the 8 branches of “Astanga Ayurveda”. It is an “Agantuja” disease, where the disease symptoms appear in 1st stage followed by its spread in the body. Thus, progress of disease (Samprapti) has been considered under concept of shatkriyakala (6 stages of disease development), which has been given high importance for deciding the stage of disease progress and its treatment protocol. Here, we have described the introduction to Astang Ayurveda, concept of disease pathogenesis and holistic approach of treatment in respect to management of COVID-19. It specifically covers symptom based stage of disease progress and its targeted treatment guideline by including all 3 approaches of treatment, described above. Here, the current line of diagnosis, treatment and research related to COVID-19 management has been included, which are reported by basic scientists and physicians of allopathic system. These are indexed in Pubmed and web of science and also described in classical text books of Ayurveda. The same has been reviewed and summarized here, with an objective of possible correlation between the 2 languages of science of health care. © 2020, National Institute of Science Communication and Information Resources. All rights reserved.